Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.64 |
| ▸ | PAM | P19021 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL3349968 | 1.00 | DGKA (0.64) | DGKAPAMTSHRMAPTCYP1A2 | |
| Methylene Chloride SCHEMBL1190981 | 0.98 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Methylene Chloride SCHEMBL3487953 | 0.98 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Methyl Alcohol SCHEMBL632314 | 0.94 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| Methyl Alcohol SCHEMBL6195522 | 0.94 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| Methyl Alcohol SCHEMBL156941 | 0.94 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| Methyl Alcohol SCHEMBL21633924 | 0.94 | DGKA (0.72) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL8375548 | 0.92 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| Hexane SCHEMBL2349171 | 0.92 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL454 | 0.92 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082515-A1 | For transcription/proliferation/differentiation of genetically engineered cells | ARIAD GENE THERAPEUTICS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6693189-B2 | NON-IMMUNOSUPPRESSIVE RAPAMYCIN DERIVATIVES | ARIAD GENE THERAPEUTICS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-6649595-B2 | FK506 binding proteins (FKBPs); rapamysin derivatives; multimerizing chimeric proteins in genetically engineered cells using said derivatives | ARIAD GENE THERAPEUTICS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020165250-A1 | Materials and method for treating or preventing pathogenic fungal infection | ARIAD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| US-20020107189-A1 | FK506 binding proteins (FKBPs); rapamysin derivatives; multimerizing chimeric proteins in genetically engineered cells using said derivatives | ARIAD PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6187757-B1 | Regulation of biological events using novel compounds | ARIAD PHARMACEUTICALS, INC. | 2001-02-13 | — | — | US | disclosed |
| US-5723462-A | SLEEP AND SEIZURE DISORDERS; COGNITION ACTIVATORS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107189-A1 | FK506 binding proteins (FKBPs); rapamysin derivatives; multimerizing chimeric proteins in genetically engineered cells using said derivatives | FKBP2, FKBP14, FKBP4 | DGKA 2013/4885PAM 4520/4885TSHR 3821/4885 |
| US-20020165250-A1 | Materials and method for treating or preventing pathogenic fungal infection | MTOR, RICTOR, RPTOR | DGKA 3442/4885PAM 3499/4885TSHR 4835/4885 |
| US-20040082515-A1 | For transcription/proliferation/differentiation of genetically engineered cells | MYC, MYCBP, RUNX1 | DGKA 724/4885PAM 4741/4885TSHR 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.